Strategic Initiative

Slingshot members are tracking this corporate initiative:

Bristol-Myers Squibb (BMY) Reaches Exclusive Worldwide Agreement with PsiOxus Therapeutics to Develop an "Armed" Oncolytic Virus NG-348 to Treat Solid Tumors

Source Link:: http://investor.bms.com/investors/news-and-events/press-releases/press-release-details/2016/Bristol-Myers-Squibb-Signs-Exclusive-Worldwide-License-Agreement-with-PsiOxus-Therapeutics-for-NG-348-an-Armed-Oncolytic-Virus-to-Address-Solid-Tumors/default.aspx

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

BMY

Community voting in process

PsiOxus Therapeutics

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Dec 20, 2016

Projected Implementation:

Q1, 2017

Relevance Tracked Until:

Q1, 2019

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Exclusive Worldwide Agreement, Ng-348, Armed Oncolytic Virus, Sold Tumors